Tribody™ Technology

The Tribody  technology enables the generation of multi-specific antibody products. This unique technology overcomes the key shortcomings of conventional mono- as well as of currently developed bi-specific antibody formats.

Tribody molecules are generated via the natural in vivo heterodimerization of Fab fragments to form a scaffold, upon which two additional binding fragments, such as scFv can be incorporated. The resulting molecules are stable and easy to produce in a single batch, without the need of additional post-production reactions other than purification. Tribodies are successfully produced in standard mammalian cell technology using well established methods.

                                         

Tribodies have several advantages compared to other bi-specific formats:

Tribodies also exhibit superior pharmacokinetics characteristics and improved therapeutic performances in experimental models: